Long-term study show the nine-valent HPV vaccine greatly reduces the risk of HPV infection and HPV-associated diseases
Cervical cancer is the second most common cause of cancer-related death worldwide, with almost 300,000 deaths occurring each year. More than 80 percent of these deaths occur in developing nations. The advent of human papillomavirus (HPV) vaccines has significantly reduced the number of those who develop and die from cervical cancer. And thanks to an international effort to improve the vaccine, the medical community is one step closer to preventing more HPV-associated diseases. The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease. The study was published this week in The Lancet.
HPV is an extremely common virus. It is estimated that by age 50, four out of five women have been infected with the virus at one point throughout their lifetimes. HPV causes ailments such as genital and anal warts and, in some instances, continued infection can lead to the development of benign or cancerous growths of the cervix, vulva, vagina, anus, penis, tonsils, and base of the tongue. There are more than 100 types of HPV, but only approximately 13 types are associated with cancer development. HPV 16 and 18 alone are estimated to cause 70 percent of all cervical cancers.
Two existing HPV vaccines, Cervarix® and Gardasil®, are effective at preventing disease caused by HPV types 16 and 18, while Gardasil also protects against genital warts caused by HPV 6 and 11. However, these vaccines do not protect against all HPV types that are associated with cancer. Scientists developed an improved vaccine called 9vHPV that targets HPV 16, 18, 6, and 11, and an additional 5 HPV types that are the next most commonly associated with cervical cancer (HPV 31, 33, 45, 52 and 58).
“Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV-related vulvar and vaginal cancer, 70 to 85 percent of high-grade cervical disease in females, and approximately 90 percent of HPV-related anal cancer and genital warts in males and females worldwide,” explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.
Researchers from 18 countries and 105 study sites conducted a phase 3 study to compare the activity of the new 9vHPV vaccine against the older vaccine that protected against four HPV types (Gardasil). The study randomized 14,215 women 16 to 26 years of age to either 9vHPV or Gardasil, and the study participants were medically followed for 6 years after vaccination.
The study found that the 9vHPV vaccine has long-term activity against HPV infection and disease. The 9vHPV vaccine reduced the risk of developing HPV 31/33/45/52/58-related cervical, vulvar, and vaginal disease by 97.7 percent when compared to Gardasil®, and the two vaccines had similar activity at preventing HPV 6/11/16/18-associated disease. The 9vHPV vaccine was also highly effective at reducing the risk of having HPV 31/33/45/52/58-associated cervical cell abnormalities, biopsies, and definitive therapies.
9vHPV, known as Gardasil 9, became available in 2015 to protect females and males ages 9 through 26 years against HPV-associated cancers and genital warts. Scientists hope its continued use will greatly reduce the incidence and mortality of HPV-associated diseases.
“The 9vHPV vaccine is licensed in over 40 countries for the prevention of HPV-related anogenital cancers and pre-cancer, and genital warts. The results of this study support comprehensive vaccination programs and inform public health decision related to implementation,” said Giuliano.
The Latest on: HPV vaccine
- Human papillomavirus (HPV) information needson February 22, 2021 at 2:52 am
With the introduction of human papillomavirus (HPV) testing and vaccination in the UK, health professionals will start to receive questions about their patients’ virus. This study aimed to identify ...
- Potential impact of a nonavalent anti HPV vaccine in Italian men with and without clinical manifestationson February 18, 2021 at 6:49 am
Nonavalent vaccine against types 6/11/16/18/31/33/45/52/58 was approved and neutral gender immunization programs have been proposed. This study evaluates the potential impact of nonavalent vaccine ...
- Rwanda: Covid-19 - Pandemic Halts HPV Vaccination in Kigalion February 18, 2021 at 12:00 am
Several challenges related to the Covid-19 pandemic have frustrated plans to roll out a vaccination programme aimed at eliminating cervical cancer causing Human Papillomavirus (HPV) for girls aged 12, ...
- Global Human Papillomavirus (HPV) Vaccines Analysis Report 2021: Supplemental Approvals Boost Opdivo And Gardasil 9, But Limit Beovuon February 17, 2021 at 12:45 pm
Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering. Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last ...
- Global Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.comon February 12, 2021 at 9:57 am
Vaccines" report has been added to ResearchAndMarkets.com's offering. Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade. There are currently ...
- Why the HPV vaccine is important for preteenson February 12, 2021 at 6:02 am
If you could protect your children now from a potential cancer later in life, would you? A recent survey conducted by the Centers for Disease Control and Prevention (CDC) reveals that an increasing ...
- Men Should Also Have Cervical Cancer Vaccineon February 11, 2021 at 1:46 am
Stating that cervical cancer is the second most common type of cancer in women under 45 years in the world, Obstetrics and Gynecology Specialist Prof. Dr.
- Global HPV Therapeutic Vaccines Market 2021 Key Players, Trends, Sales, Supply, Analysis and Forecast 2027on February 10, 2021 at 4:05 pm
WiseGuyReports.com adds "Global HPV Therapeutic Vaccines Market Research Report 2021 Analysis and Forecast 2027" reports to its database. This comprehensive market report on the HPV Therapeutic ...
- Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027on February 10, 2021 at 5:45 am
The incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market.
- Parental HPV vaccine hesitancy increased during 2012 to 2018on February 9, 2021 at 10:40 am
(HealthDay)—From 2012 to 2018, there was an increase in the proportion of unvaccinated adolescents who received a recommendation for human papillomavirus (HPV) vaccination, but parental HPV vaccine ...
via Google News and Bing News